Sacubitril/Allisartan Isoproxil |
S-086; AHU-377/EXP3174 |
Phase Ⅱ |
Salubris |
Primary hypertension |
Details
|
Daglutril |
SLV-306; KC-12615,SLV306 |
Phase Ⅱ |
Abbvie |
Pulmonary arterial hypertension, Hypertension, Heart failure |
Details
|
Z-13752A |
Z-13752A; GW-660511X |
Phase Ⅱ |
Zambon, GlaxoSmithKline |
Hypertension |
Details
|
Gemopatrilat |
BMS-189921,BMS189921 |
Phase Ⅱ |
Bristol-Myers Squibb |
Hypertension, Heart failure |
Details
|
Ecadotril |
BAY-Y-7432; S-049; BP-1.02 |
Phase Ⅲ |
Bioprojet, Bayer, Shionogi |
Hypertension, Chronic heart failure |
Details
|
RB-105 |
RB-105; S-21402; S-21402-1 |
Phase Ⅰ |
Sanofi, INSERM |
Hypertension |
Details
|
PL-265 |
PL-265 |
Phase Ⅰ |
Pharmaleads |
Neuropathic pain |
Details
|
Omapatrilat |
BMS-186716; BMS-186716-01,BMS186716 |
Phase Ⅲ |
Bristol-Myers Squibb |
Hypertension, Heart failure, Angina pectoris |
Details
|
Sch-42495 |
Sch-42495 |
Phase Ⅱ |
Merck Sharp & Dohme |
Hypertension, Heart failure |
Details
|
TD-1439 |
TD-1439 |
Phase Ⅰ |
Theravance Biopharma |
Cardiovascular disorders, Kidney disorders |
Details
|
Candoxatrilat |
UK-73967 |
Phase Ⅱ |
Pfizer |
Renal failure, Heart failure |
Details
|
Sacubitril |
AHU-377,AHU377 |
Phase Ⅱ |
Novartis |
Heart failure |
Details
|
Ilepatril |
AVE-7688; MDL-107688 |
Phase Ⅲ |
Sanofi |
Hypertension, Diabetic nephropathy |
Details
|
MDL-100240 |
MDL-100240; 100240; M-100240 |
Phase Ⅱ |
Sanofi |
Hypertension, Heart failure |
Details
|
GW-796406 |
796406; GW-796406 |
Phase Ⅰ |
Zambon, GlaxoSmithKline |
Hypertension |
Details
|
Dexecadotril |
|
Phase Ⅲ |
Bioprojet |
Gastrointestinal disorders |
Details
|
UK-447841 |
UK-447841,UK447841 |
Phase Ⅱ |
Pfizer |
Female sexual dysfunction |
Details
|
SLV-334 |
SLV-334 |
Phase Ⅱ |
Abbvie |
Brain injury |
Details
|
CGS-25462 |
CGS-25462 |
Phase Ⅱ |
Novartis |
Hypertension, Heart failure |
Details
|
ONO-9902 |
ONO-9902 |
Phase Ⅱ |
Ono Pharmaceutical |
Cancer related pain |
Details
|
Sampatrilat |
UK-81252,UK81252 |
Phase Ⅱ |
Pfizer, Shire |
Hypertension, Heart failure |
Details
|
Candoxatril |
UK-79300 |
Phase Ⅲ |
Pfizer |
Hypertension, Heart failure |
Details
|
Sch-34826 |
Sch-34826 |
Phase Ⅱ |
Merck Sharp & Dohme |
Hypertension, Heart failure |
Details
|
STR-324 |
STR-324 |
Phase Ⅰ |
Institut Pasteur, Stragen Pharma |
Pain |
Details
|
AVE-804 |
AVE-8048; M-108048; MDL-108048 |
Phase Ⅰ |
Sanofi |
Hypertension |
Details
|
PF-505749 |
PF-505749; UK-502144; UK-505749,PF 505749; UK 502144; UK 505749,PF505749; UK502144; UK505749 |
Phase Ⅰ |
Pfizer |
Female sexual dysfunction |
Details
|
TD-0714 |
TD-0714 |
Phase Ⅰ |
Theravance Biopharma |
Hypertension, Heart failure, Chronic kidney disease |
Details
|
SLV-338 |
SLV-338 |
Phase Ⅰ |
Abbott |
Cardiovascular disorders |
Details
|
Debio-0827 |
Debio-0827; PL-37,Debio0827,PL37 |
Phase Ⅱ |
Pharmaleads, Debiopharm Group |
Pain |
Details
|
Fasidotril |
BP-1.137; BP-1137,BP1137 |
Phase Ⅲ |
Bioprojet, Lilly |
Hypertension, Heart failure, Myocardial infarction (MI) |
Details
|
LHW-090 |
LHW-090; LHV-527,LHV527,LHW090 |
Phase Ⅱ |
Novartis |
Hypertension |
Details
|
VNP-489 |
VNP-489 |
Phase Ⅰ |
Novartis |
Hypertension |
Details
|